Markets

PDL BioPharma Views Lower Q2 Revenues - Analyst Blog

A generic image of a pen next to a pile of coins
Credit: Shutterstock photo

PDL BioPharma Inc. ( PDLI ) announced that it expects to generate revenues of roughly $140 million in the second quarter of 2014, down roughly 3% year over year. The expected revenues are however above the current Zacks Consensus Estimate of $131 million.

PDL BioPharma receives royalties from companies like Roche Holdings ( RHHBY ) and Novartis ( NVS ). The royalties are earned on worldwide net sales of products like Avastin, Herceptin, Xolair, Kadcyla, Actemra and Perjeta.

PDL BioPharma attributes the decrease in royalty revenues in the quarter to the fixed rate of 2.125% currently being applied on net sales of Roche's Avastin, Herceptin, Lucentis, Xolair, Perjeta and Kadcyla.

According to the agreement with Roche, inked in Feb 2014, and effective retroactively to Aug 15, 2013, PDL BioPharma will receive a fixed royalty rate of 2.125% on global sales of Avastin, Herceptin, Lucentis Xolair, Kadcyla and Perjeta from Roche. Previously royalties on Roche's products were tiered 1-3% in the U.S. and flat 3% in the ex-U.S. markets. PDL BioPharma is expected to recognize royalties till the first quarter of 2016.

PDL BioPharma however stated that second quarter royalty revenues will increase on a sequential basis. The anticipated growth in royalty revenues primarily emanates from higher sales of Herceptin (up 3%), Avastin (up 9%), Kadcyla (up 446%), Perjeta (up 275%) and Actemra (up 37%) during the first quarter of 2014 for which PDL will receive royalties in the second quarter.

PDL BioPharma recognizes royalty revenues on Glumetza (as per a deal in Oct 2013) a month after sales by the licensees have been booked. The company expects $25 million of royalty revenues from sales of Glumetza in the second quarter of 2014.

Effective from the second quarter of 2011, PDL BioPharma started paying back a portion of the royalties it receives on Lucentis sales outside the U.S. to Novartis. The payment is made in accordance to a settlement agreement, which the companies had entered in Feb 2011. The amount paid is less than what PDL BioPharma received in royalties.

PDL BioPharma currently carries a Zacks Rank #3 (Hold). A better ranked biopharma stock is Alexion Pharmaceuticals, Inc. ( ALXN ) with a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

PDL BIOPHARMA (PDLI): Free Stock Analysis Report

ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report

ALEXION PHARMA (ALXN): Free Stock Analysis Report

NOVARTIS AG-ADR (NVS): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

RHHBY PDLI ALXN NVS

Other Topics

Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More